Comment from National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL)

Summary: The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) supports the draft guidance and suggests specific improvements to enhance its clarity and practical adoption. They recommend adding a glossary of key terms, providing clearer guidance on third-party vendor proprietary information, and making performance estimate requirements proportionate to the model's risk level.